- Home
- LGCL vs ATNM Comparison
LGCL vs ATNM Comparison
Compare LGCL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- ATNM
- Stock Information
- Founded
- LGCL 2009
- ATNM 2000
- Country
- LGCL China
- ATNM United States
- Employees
- LGCL N/A
- ATNM N/A
- Industry
- LGCL
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- LGCL
- ATNM Health Care
- Exchange
- LGCL NYSE
- ATNM Nasdaq
- Market Cap
- LGCL 47.7M
- ATNM 51.5M
- IPO Year
- LGCL 2024
- ATNM N/A
- Fundamental
- Price
- LGCL $0.96
- ATNM $1.40
- Analyst Decision
- LGCL
- ATNM Strong Buy
- Analyst Count
- LGCL 0
- ATNM 3
- Target Price
- LGCL N/A
- ATNM $4.67
- AVG Volume (30 Days)
- LGCL 832.5K
- ATNM 494.1K
- Earning Date
- LGCL 01-01-0001
- ATNM 08-04-2025
- Dividend Yield
- LGCL N/A
- ATNM N/A
- EPS Growth
- LGCL N/A
- ATNM N/A
- EPS
- LGCL 0.07
- ATNM N/A
- Revenue
- LGCL $145,690,427.00
- ATNM N/A
- Revenue This Year
- LGCL N/A
- ATNM N/A
- Revenue Next Year
- LGCL N/A
- ATNM N/A
- P/E Ratio
- LGCL $18.10
- ATNM N/A
- Revenue Growth
- LGCL N/A
- ATNM N/A
- 52 Week Low
- LGCL $0.28
- ATNM $1.03
- 52 Week High
- LGCL $3.31
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- ATNM 49.77
- Support Level
- LGCL N/A
- ATNM $1.48
- Resistance Level
- LGCL N/A
- ATNM $1.95
- Average True Range (ATR)
- LGCL 0.00
- ATNM 0.12
- MACD
- LGCL 0.00
- ATNM -0.01
- Stochastic Oscillator
- LGCL 0.00
- ATNM 33.64
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.